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Incorporating costs into healthcare decision-making is assum-
ing increasing importance in infectious diseases and clinical
microbiology, as in other medical domains. With the intro-
duction of novel, costly molecular diagnostics and with an
increasing need for tighter infection control, cost conside-
rations will become even more important. There are special
problems when attempting to assess costs or cost-effectiveness
of interventions in infectious diseases, and a dearth of guidance
on how to conduct such studies appropriately. The spectrum
of disease ranges from acute infections occurring in the hospital
to chronic, life-long conditions (e.g. human immunodeﬁciency
virus (HIV) disease). The breadth of indirect costs surround-
ing infections in hospital or in the community is undeﬁned.
Resistance development following antibiotic treatment and
its effects on the individual, the microenvironment and the
macroenvironment is difﬁcult to incorporate in cost-effective-
ness analyses, just as in clinical studies.
A review of studies whose primary aim was to assess costs,
cost-effectiveness or other costs analyses in the top ten jour-
nals publishing original studies in infectious diseases in the last
5 years (Journal Citation Reports 2009, ranked by impact fac-
tor) revealed 95 studies, most of which were published in the
last year. The large majority of the studies (47%) addressed
HIV disease prevention (13 studies) and treatment (32 studies)
in developing countries (32; 71% of studies on HIV). Other
main ﬁelds were rotavirus vaccine or management (11 studies,
eight in developing countries), inﬂuenza (mainly prevention,
seven studies) and management of hepatitis (six studies), the
last two being conducted solely in developed countries. Only
seven studies assessed antibiotic treatment for various acute
bacterial or fungal infections, and another seven studies
addressed very different aspects related to hospital-acquired
infections (methicillin-resistant Staphylococcus aureus (MRSA)
screening (2), methicillin-sensitive S. aureus or MRSA bactera-
emia (2), and one each on surgical site infections, Clostridium
difﬁcile and an antimicrobial stewardship team), all in devel-
oped counties. A single study addressed costs attributable to
antimicrobial-resistant infections in hospitals in the USA [1].
In 56 studies whose design was based on a model, the ref-
erence case reported in most studies was primarily cost/
quality-adjusted life-years (QALYs; 55% of studies). Eight
studies, all of which dealt with HIV management, reported
primarily on costs per life-year. Clinical studies whose pri-
mary aim was cost analysis reported most commonly simply
on the costs of an infection or a management strategy (27/
39 studies; 69%). Fifteen studies overall (16%) reported on
cost/outcome avoided (infection, treatment failure or dis-
ease-related death). These studies used intermediary mea-
sures of outcome that are difﬁcult to compare with other
studies and interventions.
The perspective in the studies was most commonly the
provider’s (the hospital, healthcare organization or govern-
ment in 56/94 studies; 60%). The costs considered were
those of medications, testing, personnel or clinic visits/hospi-
tal days. A societal perspective, considering some, although
usually not all, indirect medical and non-medical costs was
reported in 34% of studies, and more commonly in studies
on HIV disease management (13/32, 40%). Five studies
reported that the analysis was performed from the patient’s
perspective. These studies added cost components, such as
transportation, food, loss of income and assets, reduced pro-
ductivity and other out-of-pocket expenditure of the family,
that were not included in studies reporting on the societal
perspective. Studies on antibiotic treatment and hospital-
acquired infections reported more frequently only the pro-
vider’s perspective (13/16 studies; 81%) than did other stud-
ies dealing with HIV, vaccines, inﬂuenza and other viral
infections (44/79; 56%).
It is interesting to note that of 67 studies that aimed to
assess the cost-effectiveness of a speciﬁc intervention (treat-
ment, vaccine, prevention strategy), 53 (79%) reported the
intervention to be cost-effective in the base case analysis
(the basic analysis incorporating data and methods best rep-
resenting the interventions and choices under consideration).
Another seven studies concluded that the intervention was
cost-effective under most assumptions. Only three studies
reported a negative result for the base case, and another
four studies gave negative conclusions for most of the sce-
narios assessed in sensitivity analyses. The information con-
veyed in the negative studies is rather interesting and useful
ª2010 The Author
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases
EDITORIAL 10.1111/j.1469-0691.2010.03354.x
for decision-makers. Two studies, published in this issue,
found that rapid screening with PCR for MRSA was not
cost-effective in Switzerland and The Netherlands [2,3]. One
study reported that the incremental cost-effectiveness ratio
for PCR screening at admission of surgical patients was
nearly $30 000 per MRSA infection avoided [2], and the
other reported that PCR-based screening of patients at risk
cost between $125 and 163$ per isolation day avoided [3].
HIV pre-exposure prophylaxis with tenofovir–emtricitabine
in the USA [4] and post-exposure prophylaxis in France
were not cost-effective [5], considering costs/QALY from a
societal perspective. Seasonal targeted blood screening for
West Nile virus (WNV) was estimated to cost between
$91 500 per QALY gained among immunocompromised
patients and $4 million in the general population [6],
whereas WNV vaccination cost $35 000 per case of WNV
illness prevented [7]. The cost for one round of screening
for hepatitis C and treatment in prisons in England and
Wales was about $86 000/QALY, and was considered to be
essentially not cost-effective [8].
Inspection of the studies published recently in leading infec-
tious disease journals highlights the lack of studies addressing
the burden of hospital-acquired infections and antimicrobial
resistance. The review articles published in this issue address
the special difﬁculties and pitfalls in the conduct of such stud-
ies [9–13]. There is large variability in the reference case
reported in existing studies, as reﬂected in three studies in
this issue reporting on the cost-effectiveness of MRSA
screening, giving costs per infection avoided, costs per isola-
tion day avoided, or crude costs [2,3,14]. Different reference
standards make comparisons between studies, locations and
interventions difﬁcult. Recommendations on the reporting of
cost-effectiveness analyses in general have been published
[15–17]. There is a need for consensus guidelines on the con-
duct and reporting of such studies in infectious diseases.
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